For the past 12 years, Grattoni’s work has focused on implantable nanochannel platforms to control the delivery of therapies for a variety of chronic medical needs, including HIV-prevention, muscle atrophy, obesity and cancer. One of his studies, a collaboration with E. Brian Butler, MD, chair of the Department of Radiation Oncology, and the University of Texas MD Anderson, established a novel strategy using a nanodevice to deliver immunotherapy directly to a tumor to treat triple-negative breast cancer without side effects. The implantable nanodevice is placed inside the tumor to provide sustained delivery of immunotherapy over a prolonged period of time without requiring the patient to return for numerous treatments. Grattoni is already collaborating with Lamborghini on another project to study the biocompatibility of the automaker’s proprietary carbon fiber composites for implantable devices. Understanding the durability of Lamborghini’s proprietary material in accelerated and extreme environmental conditions in space could help future research efforts for biomedical technologies beyond drug-delivery devices, such as in prostheses and in dental and orthopedic implants.